Ganglionic eminence initially appears as a slight swelling in the floor of the cerebral vesicle during the 5th fetal week and attains maximum prominence late in the 4th fetal month; it then declines in relative size, and nearly disappears after birth. The ganglionic eminence constitutes a collection of the proliferating cells throughout most of span of gestation and supply neuroblasts and spongioblasts to basal ganglia and pulvinar region of thalamus and cerebral cortex. Nowadays intraventricular hemorrhage predominantly occurs in preterm infants of less than 32 weeks gestational age, and the intraventricular hemorrhage arises most frequently from rupture of a ganglionic eminence hemorrhage is equally frequent in both hemispheres and is associated with an extensive destruction of the capillary bed without arterial or venous rupture. Although fibrin thrombi are seen within veins in relation to ruptures at the capillary vein junction, the other study reveals little or no fibrin is to be seen within the ganglionic eminence hemorrhage presumably due to the high fibrinolytic activity within this region of the immature brain. Accordingly this study was planned to evaluate the ganglionic eminence of fetal brain in two aspects, i.e., morphological development of ganglionic eminence during gestation and functional maturation by measuring fibrinolytic activity of various portions of developing brains. To evaluate the development of ganglionic eminence a total of 97 brains of Korean fetuses of gestational ages ranging from 16 to 37 weeks, was studied; 62 for morphological study and 35 for functional study. The fetuses were products of therapeutic abortions, and were proved to be normal after complete examination of fetuses and placentas. The brains were removed as soon as possible after delivery, and were fixed in 10% formalin for 1 to 2 weeks before being examined. Representative blocks containing white matte around lateral ventricle, ganglionic eminence, caudate nucleus and thalamus on the serial coronal sections. Through routine histological procedure, slides were made and stained with hematoxylin and eosin for microscopical examination of the ganglionic eminence and striatum. The fibrionlytic activity of the tissue was measured by fibrin plate method of Astrup and Albrechtsen and the amount of lysis expressed as area/mg of wet tissues. As controls comparable aliquots of 2M potassium thiocyanate or saline alone had no fibrinolytic activity. To detect the in vivo fibrinolysis, fibrin and/or fibrinogen degradation product, staphylococcal clumping tests for the tissue extracts were performed. Following results were obtained. 1) The ganglionic eminence was well formed and located at the lateral side of terminal vein and over the caudate nucleus and protruded into the lateral ventricle. 2) The thickness of the ganglionic eminence is reached to maximum width by 20th week of gestation and is shown a progressive reduction till 30th week, and revealed sharp reduction after 31th week of gestation and became no longer recognizable after 37th week of gestation. 3) The ependymal layer was most thickened at 16~19th week of gestation, showing 6~8 layers with numerous mitoses and declined to 2~3 layers at 28~31th week of gestation and no more mitosis was found. 4) The distribution of capillary beds were most pronounced at 16~19th week of gestation and the permeation of the capillaries to the ependymal zone and decreased in number after 20th week of gestation. The medium sized, well developed veins were demonstrable at the junction of ganglionic eminence and caudate nucleus from 24th week of gestation. 5) The fibrinolytic activity of the choroid plexus and leptomeninges were significantly increased than the other areas(p<0.005) and there was no evidence of gestational changes. 6) The fibrinolytic activity of the ganglionic eminence was no more pronounced than those of cerebral cortex, periventricular white matter, cerebellum and spinal cord.
Infant ; Male ; Female ; Humans

Iron in plasma cells has been described in patients with diseases characterized by iron overload. We observed iron-containing plasma cells in the bone marrow aspirates of 6 patients with anemia. In five of these 6 patients, there were alcoholic liver disease and in one there was abdominal aortic occlusion. Medical records of patients and previous reports were reviewed. Marrow storage irons were adequate or increased, but other morphologic changes of alcoholism such as erythroid vacuolization or ringed sideroblasts were not the features. The presence of iron-containing plasma cells is suggestive of alcoholism and its complications, and diseases associated with iron overload or inability of RBCs to utilize iron. The exact mechanism of entry of iron into plasma cells is controversial.
Alcoholism ; Anemia ; Bone Marrow ; Humans ; Iron Overload ; Iron* ; Liver Diseases, Alcoholic ; Medical Records ; Plasma Cells* ; Plasma*

BACKGROUND: The differential diagnosis of clonal and reactive thrombocytosis is clinically relevant because course and treatment are different between them. Several clinical assessments and laboratory tests (degree of such as splenomegaly, duration and degree of thrombocytosis, bone marrow study, cytogenetic study, and platelet function test) are less discriminative, invasive and not commonly available. Therefore, a well discriminative, simple and convenient diagnositic assay is needed. Recently animal experiments demonstrated that recombinant IL-6 administration increased platelets counts by stimulating megakaryocyte maturation and increased hepatic CRP synthesis. So, in this study, we evaluated the usefulness of measurements of IL-6 and CRP levels to distinguish reactive thrombocytosis from clonal thrombocytosis. METHODS: Included in this study were 88 patients with marked thromobocytosis (>600 x10(9)/L) at Asan Medical Center between September, 1995 and March, 1996. The cause of thrombocytosis was determined by reviewing the medical histories. Sixteen patients had clonal thrombocytosis and 72 patients had reactive thrombocytosis. IL-6 was measured by ELISA (Quantikine(TM), R&D system, Inc., Minneapolis, USA) and CRP was assayed by rate immunonephelometry (Array 360 system, Beckman Instruments Inc., USA). RESULTS: The patients with reactive thrombocytosis had significantly higher plasma levels of IL-6 and CRP than patients with clonal thrombocytosis (p<0.01, p<0.001). In 98.6% (71/72) of the patients with reactive thromobocytosis, levels of either IL-6 or CRP were elevated, and 43.8% (7/16) of the patients with clonal thrombocytosis had both IL-6 and CRP in normal range. Of 9 patients with clonal thrombocytosis (56.2%) whose levels of either IL-6 or CRP increased, 7 patients had concomitant acute phase reaction such as infection or post operative status. There was significant correlation between IL-6 and CRP levels (r2=0.4, p<0.0001). CONCLUSION: Elevated levels of either IL-6 or CRP were consistent with reactive thrombocytosis and normal ranges of those suggested clonal thrombocytosis. So measurement of plasma IL-6 and CRP levels is a useful marker for differential diagnosis of clonal and reactive thrombocytosis. For the patients with clonal thrombocytosis who had concomitant acute phase reaction, serial measurements are recommended.
Acute-Phase Reaction ; Animal Experimentation ; Blood Platelets ; Bone Marrow ; C-Reactive Protein* ; Chungcheongnam-do ; Cytogenetics ; Diagnosis, Differential* ; Enzyme-Linked Immunosorbent Assay ; Humans ; Interleukin-6* ; Megakaryocytes ; Plasma* ; Reference Values ; Splenomegaly ; Thrombocytosis*

No abstract available.

No abstract available.
Antibodies*

No abstract available.
Bone Marrow* ; Hodgkin Disease*

No abstract available.
Lupus Coagulation Inhibitor*

No abstract available.
DNA* ; Flow Cytometry*

No abstract available.
DNA* ; Flow Cytometry*

We report a case of weak subgroup A in a patient diagnosed as myelodysplastic syndrome. The patient's red cells was typed as O and his serum had anti-B. Red blood cell antibody screening test was negative. Am was confirmed by adsorption-elution test and saliva study.
Erythrocytes ; Humans ; Mass Screening ; Myelodysplastic Syndromes ; Saliva